Abstract

BackgroundPublicly available genomics datasets have grown drastically during the past decades. Although most of these datasets were initially generated to answer a pre-defined scientific question, their repurposing can be useful when new challenges such as COVID-19 arise. While the establishment and use of experimental models of COVID-19 are in progress, the potential hypotheses for mechanisms of onset and progression of COVID-19 can be generated by using in silico analysis of known molecular changes during COVID-19 and targets for SARS-CoV-2 invasion.MethodsSelecting condition: COVID-19 infection leads to pneumonia and mechanical ventilation (PMV) and associated with acute kidney injury (AKI). There is increasing data demonstrating mechanistic links between AKI and lung injury caused by mechanical ventilation.Selecting targets: SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) for cell entry. We hypothesized that expression of ACE2 and TMPRSS2 would be affected in models of AKI and PMV. We therefore evaluated expression of ACE2 and TMPRSS2 as well as other novel molecular players of AKI and AKI-lung cross-talk in the publicly available microarray datasets GSE6730 and GSE60088, which represent gene expression of lungs and kidneys in mouse models of AKI and PMV, respectively.ResultsExpression of COVID-19 related genes ACE2 and TMPRSS2 was downregulated in lungs after 6 h of distant AKI effects. The expression of ACE2 decreased further after 36 h, while expression of TMPRSS2 recovered. In kidneys, both genes were downregulated by AKI, but not by distant lung injury. We also identified 53 kidney genes upregulated by PMV; and 254 lung genes upregulated by AKI, 9 genes of which were common to both organs. 3 of 9 genes were previously linked to kidney-lung cross-talk: Lcn2 (Fold Change (FC)Lung (L) = 18.6, FCKidney (K) = 6.32), Socs3 (FCL = 10.5, FCK = 10.4), Inhbb (FCL = 6.20, FCK = 6.17). This finding validates the current approach and reveals 6 new candidates, including Maff (FCL = 7.21, FCK = 5.98).ConclusionsUsing our in silico approach, we identified changes in COVID-19 related genes ACE2 and TMPRSS2 in traditional mouse models of AKI and kidney-lung cross-talk. We also found changes in new candidate genes, which could be involved in the combined kidney-lung injury during COVID-19.

Highlights

  • Available genomics datasets have grown drastically during the past decades

  • Expression of Corona virus disease (COVID)-19 related genes angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) was downregulated in lungs after 6 h of distant Acute kidney injury (AKI) effects

  • We identified 53 kidney genes upregulated by pneumonia and mechanical ventilation (PMV); and 254 lung genes upregulated by AKI, 9 genes of which were common to both organs. 3 of 9 genes were previously linked to kidney-lung cross-talk: Lcn2 (Fold Change (FC)Lung (L) = 18.6, ­FCKidney (K) = 6.32), Suppressor of cytokine signaling 3 (Socs3) ­(FCL = 10.5, ­FCK = 10.4), Inhbb (­FCL = 6.20, ­FCK = 6.17)

Read more

Summary

Introduction

Available genomics datasets have grown drastically during the past decades Most of these datasets were initially generated to answer a pre-defined scientific question, their repurposing can be useful when new challenges such as COVID-19 arise. Grigoryev and Rabb BMC Nephrology (2022) 23:57 new challenges such as COVID-19 arise and need to be rapidly dealt with These data sets are very useful to study when traditional wet-lab research is slowed down during the pandemic, and experimental models of COVID-19 are still under development. Acute kidney injury (AKI) is associated with COVID-19 This association is thought to be secondary to hemodynamic effects of the disease related septic condition, and the poor outcome is secondary to sepsis, where AKI is often a surrogate marker of severity of illness in these patients [2, 3]. The critical illness during COVID-19 warrants study COVID-19 related genes and kidney-lung cross-talk to discover potential therapeutic targets

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call